Navigation Links
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Date:5/10/2013

ctions into the brain of NSI-566. The INDs for both acute spinal cord injury Phase I/II in Seoul and ALS Phase I/II in Mexico City are expected to be filed in June.

"Additionally, we were approved by the FDA to treat the third and final cohort of the ongoing Phase Ib major depressive disorder trial with our lead neurogenic small molecule compound, NSI-189. Dosing is proceeding well, and we expect to complete the trial in September," Dr. Johe concluded.

"This past quarter we were pleased to grant licenses for our proprietary intraspinal cell therapy surgical devices and method, used in the Phase I NSI-566/ALS trial, to Cedars-Sinai Medical Center. The licenses are specifically for academic research, enabling a new era of research and treatment of spinal cord conditions and diseases," stated Richard Garr , Neuralstem President and CEO. "Additionally, we further strengthened our substantial global IP portfolio to include five licensed patent grants in Europe for the floating cannula and cell therapy method of use. Our newest U.S. patent covers the use of expanded spinal cord stem cells to treat ALS and joins past patent claims covering methods of culturing and treating neurodegenerative conditions with our NSI-566 cells. In our neurogenic small molecule program, we received one U.S. patent covering divisional compositions and methods of use, and 11 European patents for method of discovering neurogenic agents.

"Finally, Dr. Johe and I would like to thank our  scientific and medical collaborators, and the patients and their families in the ALS community who believe in the science, technology and promise of Neuralstem for appearing at the recent FDA hearing on ALS trials and being vocal with their support," added Garr. 

First Quarter Clinical Program and Business Highlights In January, Neuralstem's lead cell therapy candidate,
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
6. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
7. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
8. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
9. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
10. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... June 21 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... drug development company specialized in oncology and endocrinology, announced ... direct offering of US$12.1 million of units ... to certain institutional investors. Net proceeds from this offering, ...
... Fla. , June 21 Dyadic International, ... cutting-edge C1 platform technology addresses the needs of the ... scale which efficiently convert biomass into ethanol and other ... engaged the influential consulting firm, The Abraham Group, to ...
... WA , and VANCOUVER , June 21 ... ) announced today the initiation of a Phase 3 ... candidate being developed for the treatment of castrate-resistant prostate ... Cancer SATURN Trial, is the first of three Phase ...
Cached Biology Technology:Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 2Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 3Dyadic International Engages The Abraham Group as Strategic Advisor 2Dyadic International Engages The Abraham Group as Strategic Advisor 3Dyadic International Engages The Abraham Group as Strategic Advisor 4OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 5
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014 /PRNewswire/ ... the publication of a study that pinpoints fine-scale differences ... the United States . Since immigrants ... the United States has served as ... study illuminates how American history and the ongoing mixing ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... species within a community and are commonly transmitted ... pathogen emergence and therefore has been considered as ... of agricultural importance. Many pathogens like malaria, Lyme ... hosts are commonly transmitted by vectors, and their ...
... Researchers at Yale, in collaboration with NIH researchers, have ... the immune system for detection of parasitic infections, leading ... these infections. , Published in the April 28 issue ... how infectious parasites interface with the immune system--a problem ...
... shows that farmers who used agricultural insecticides experienced ... longer using the products. Data from 18,782 North ... including organophosphates and organochlorines, to reports of reoccurring ... and other neurological symptoms. Some of the insecticides ...
Cached Biology News:A new study examines how shared pathogens affect host populations 2Yale researchers identify molecule for detecting parasitic infection in humans 2Use of Insecticides Linked to Lasting Neurological Problems for Farmers 2
Values of steady state parameters for enzyme activities are determined....
... (PPAR) is a member of a ... factors that heterodimerize with retinoic acid-like ... the regulation of glucose and lipid ... of anti-diabetic agents called thiazolidinediones (TZD) ...
... This protein identification Service includes 1. ... protein spots 3. High-sensitive tryptic in-gel ... of samples for MALDI-MS 5. Acquisition ... via MALDI-MS (Bruker ultraflex TOF/TOF) 6. ...
... Preparation Reconstitution: one vial contains ... ficoll and 50 mg PVP; ... water yields a 50concentrate Special ... 1.00 g/mL (20 C) Quality ...
Biology Products: